ID: ALA1628103
Max Phase: Preclinical
Molecular Formula: C30H44B2F8O3Rh
Molecular Weight: 729.19
Molecule Type: Small molecule
Associated Items:
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Molecular Weight: 729.19 | Molecular Weight (Monoisotopic): 729.2404 | AlogP: | #Rotatable Bonds: |
| Polar Surface Area: | Molecular Species: | HBA: | HBD: |
| #RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
| CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
| Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
| 1. el Amouri H, Vessières A, Vichard D, Top S, Gruselle M, Jaouen G.. (1992) Syntheses and affinities of novel organometallic-labeled estradiol derivatives: a structure-affinity relationship., 35 (17): [PMID:1507201] [10.1021/jm00095a006] |
Source(1):
